Jim Wassil Sells 3,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVXGet Free Report) COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.88, for a total transaction of $221,640.00. Following the completion of the sale, the chief operating officer now directly owns 175,935 shares in the company, valued at approximately $12,998,077.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jim Wassil also recently made the following trade(s):

  • On Tuesday, January 2nd, Jim Wassil sold 3,000 shares of Vaxcyte stock. The stock was sold at an average price of $63.91, for a total transaction of $191,730.00.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $74.83 on Wednesday. The company has a market capitalization of $7.12 billion, a P/E ratio of -22.40 and a beta of 0.93. The company has a fifty day moving average of $61.84 and a 200-day moving average of $53.69. Vaxcyte, Inc. has a 52-week low of $34.11 and a 52-week high of $76.72.

Vaxcyte (NASDAQ:PCVXGet Free Report) last posted its quarterly earnings results on Monday, November 6th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.07). As a group, analysts forecast that Vaxcyte, Inc. will post -3.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on PCVX shares. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price objective on shares of Vaxcyte in a research note on Tuesday, November 7th. Mizuho began coverage on shares of Vaxcyte in a research report on Thursday, December 7th. They set a “buy” rating and a $69.00 price target for the company. Bank of America boosted their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and an average target price of $68.40.

Read Our Latest Stock Analysis on PCVX

Institutional Trading of Vaxcyte

Several hedge funds have recently added to or reduced their stakes in the business. Xponance Inc. lifted its stake in Vaxcyte by 3.0% in the fourth quarter. Xponance Inc. now owns 5,672 shares of the company’s stock worth $356,000 after purchasing an additional 163 shares during the last quarter. Ellsworth Advisors LLC raised its stake in shares of Vaxcyte by 2.6% during the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock valued at $506,000 after acquiring an additional 207 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Vaxcyte by 0.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock valued at $3,211,000 after acquiring an additional 296 shares during the last quarter. Strs Ohio raised its stake in shares of Vaxcyte by 3.9% during the fourth quarter. Strs Ohio now owns 10,700 shares of the company’s stock valued at $671,000 after acquiring an additional 400 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Vaxcyte by 0.6% during the third quarter. Alps Advisors Inc. now owns 69,305 shares of the company’s stock valued at $3,533,000 after acquiring an additional 426 shares during the last quarter.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Featured Stories

Insider Buying and Selling by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.